FREQUENCY AND SEVERITY OF DYSPEPTIC SYMPTOMS AMONG PATIENTS TAKING LOW-DOSE ACETYLSALICYLIC ACID FOR CARDIOVASCULAR PREVENTION: THE OBERON TRIAL

(1) University of Michigan Hospita, Gastroenterology, Ann Arbor, USA

(2) Department of Molecular and Clinical Medicine/Cardiology, Institution of Medicine, Sahlgren

(3) Department of Medicine, OsloUniversity Hospital, Oslo, Norway

(4) Department of Medicine, University of Zaragoza, Zaragoza, Spain

(5) University of Alberta, Edmonton, Canada

(6) Statistics and Informatics, AstraZeneca R&D, Mölndal, Sweden

(7) AstraZeneca R&D, Mölndal, Sweden



This item was part of the Oesophageal, Gastric and Duodenal Disorders III session at UEG Week Barcelona 2010

This item can be cited as: Gut 2010; 59 (Suppl III) A339

You may be interested in:

Vifor - Practical management of anemia after a GI bleed (Vifor Pharma)
English, Presentation, Industry Sponsored Symposia, Industry Sponsored Symposia, 2019, Vifor Pharma

Categorisation:

  • Format
    • Abstract
  • Language
    • English
  • Year
    • 2010